Physician profile
Kyle Owens
NPI 1497286322
$51,179.60
in general payments reported to CMS, 2019-2025
27 companies · $43K in 2025
The $43K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.01 · 2020: $18.72 · 2021: $615 · 2022: $1,091 · 2023: $3,266 · 2024: $3,507 · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Food and Beverage: $11K · Consulting Fee: $1,900 · Education: $395 · Travel and Lodging: $53.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,950.00 |
| Food and Beverage | $11,134.97 |
| Consulting Fee | $1,900.00 |
| Education | $394.62 |
| Travel and Lodging | $53.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $33,469.33 | 2022-2025 | Nemluvio, Aklief, Dysport |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $6,118.65 | 2021-2025 | Cabtreo, Siliq, Arazlo |
| Leo Pharma INC. | $2,789.24 | 2022-2025 | Adbry, Anzupgo, Spevigo |
| Abbvie INC. | $2,262.50 | 2021-2025 | |
| Janssen Biotech, INC. | $1,343.98 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Sun Pharmaceutical Industries INC. | $822.99 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Amgen INC. | $740.27 | 2022-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $633.21 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $599.72 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $407.69 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $304.61 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $301.43 | 2023-2025 | |
| Lilly USA, LLC | $288.43 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $165.28 | 2022-2025 | Opzelura |
| Genzyme Corporation | $152.46 | 2021-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $125.79 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $123.80 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.44 | 2023-2025 | Spevigo, Cyltezo |
| Revance Therapeutics, INC. | $96.36 | 2024-2025 | Daxxify |
| Almirall LLC | $72.47 | 2024-2025 | Klisyri, Seysara |
| Mayne Pharma Commercial LLC | $65.61 | 2023-2025 | |
| Biofrontera INC. | $63.22 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Genentech USA, INC. | $40.73 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $23.86 | 2023 | Ycanth |
| Fidia Pharma USA INC. | $20.22 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $18.59 | 2024 | Valchlor |
| Botanix Sb INC | $15.72 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Owens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.